Roche/Antisoma Ovarian Cancer Phase III Failure Likely To End Development
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Development for Roche/Antisoma’s ovarian cancer agent R-1549 is "unlikely" to continue following the biologic’s failure to meet primary endpoints in a pivotal Phase III trial, the companies said April 26.